SI3337477T1 - Sestavki, ki vsebujejo inhibitorje fosfoinozitid 3-kinaze in drugo antiproliferativno sredstvo - Google Patents

Sestavki, ki vsebujejo inhibitorje fosfoinozitid 3-kinaze in drugo antiproliferativno sredstvo

Info

Publication number
SI3337477T1
SI3337477T1 SI201631666T SI201631666T SI3337477T1 SI 3337477 T1 SI3337477 T1 SI 3337477T1 SI 201631666 T SI201631666 T SI 201631666T SI 201631666 T SI201631666 T SI 201631666T SI 3337477 T1 SI3337477 T1 SI 3337477T1
Authority
SI
Slovenia
Prior art keywords
phosphoinositide
compositions
kinase inhibitors
antiproliferative agent
antiproliferative
Prior art date
Application number
SI201631666T
Other languages
English (en)
Slovenian (sl)
Inventor
Stephen Joseph Shuttleworth
Andrew David Whale
Original Assignee
Convalife (Shanghai) Co. Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convalife (Shanghai) Co. Limited filed Critical Convalife (Shanghai) Co. Limited
Publication of SI3337477T1 publication Critical patent/SI3337477T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201631666T 2015-08-19 2016-08-19 Sestavki, ki vsebujejo inhibitorje fosfoinozitid 3-kinaze in drugo antiproliferativno sredstvo SI3337477T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
EP16756763.5A EP3337477B1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Publications (1)

Publication Number Publication Date
SI3337477T1 true SI3337477T1 (sl) 2023-04-28

Family

ID=54258859

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631666T SI3337477T1 (sl) 2015-08-19 2016-08-19 Sestavki, ki vsebujejo inhibitorje fosfoinozitid 3-kinaze in drugo antiproliferativno sredstvo

Country Status (22)

Country Link
US (3) US10668077B2 (enExample)
EP (1) EP3337477B1 (enExample)
JP (1) JP2018523689A (enExample)
KR (1) KR20180064387A (enExample)
CN (2) CN113786409B (enExample)
AU (1) AU2016307885B2 (enExample)
CA (1) CA2995898A1 (enExample)
DK (1) DK3337477T3 (enExample)
ES (1) ES2939815T3 (enExample)
FI (1) FI3337477T3 (enExample)
GB (1) GB201514760D0 (enExample)
HR (1) HRP20230376T1 (enExample)
HU (1) HUE061615T2 (enExample)
IL (1) IL257499A (enExample)
LT (1) LT3337477T (enExample)
MX (1) MX2018001926A (enExample)
PL (1) PL3337477T3 (enExample)
PT (1) PT3337477T (enExample)
RS (1) RS64095B1 (enExample)
SI (1) SI3337477T1 (enExample)
SM (1) SMT202300063T1 (enExample)
WO (1) WO2017029517A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534326T3 (es) 2009-08-20 2015-04-21 Karus Therapeutics Limited Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
BR112021004371A2 (pt) * 2018-09-11 2021-05-25 Curis Inc. terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
WO2020059705A1 (ja) * 2018-09-18 2020-03-26 株式会社ヤクルト本社 キノリンカルボキサミド誘導体を用いるがん併用療法
WO2020174420A1 (en) * 2019-02-27 2020-09-03 Astrazeneca Ab Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
GB201909468D0 (en) * 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
DE60039357D1 (de) 1999-08-03 2008-08-14 Lilly Icos Llc Pharmazeutische zusammensetzung enthaltend tadalafil
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
CA2414468A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2005217320B2 (en) 2004-02-26 2011-07-21 Aska Pharmaceuticals Co., Ltd. Pyrimidine derivative
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ564065A (en) 2005-05-20 2011-03-31 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
BRPI0710866A2 (pt) 2006-04-26 2012-08-14 Hoffmann La Roche compostos farmacÊuticos
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
CN101501035B (zh) * 2006-08-08 2013-01-23 中外制药株式会社 作为pi3k抑制剂的嘧啶衍生物及其用途
EP2441768A1 (en) 2006-11-13 2012-04-18 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
JP2010518014A (ja) 2007-01-31 2010-05-27 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用な２−アミノピリジン誘導体
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
EP2205242B1 (en) * 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
ES2534326T3 (es) * 2009-08-20 2015-04-21 Karus Therapeutics Limited Compuestos tricíclicos heterocíclicos como inhibidores de la fosfoinositida 3-cinasa
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN105175396B (zh) 2011-07-27 2018-01-16 阿斯利康(瑞典)有限公司 取代的4‑甲氧基‑n3‑(嘧啶‑2‑基)苯‑1,3‑二胺化合物及其盐
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PL2994465T3 (pl) 2013-05-10 2019-01-31 Karus Therapeutics Limited Nowe inhibitory deacetylazy histonowej
BR112015029969A2 (pt) * 2013-05-30 2017-07-25 Infinity Pharmaceuticals Inc tratamento de câncer usando moduladores de isoformas quinase pi3
EP3052494B1 (en) 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
US9403779B2 (en) 2013-10-08 2016-08-02 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors
ES2818933T3 (es) 2013-10-10 2021-04-14 Acetylon Pharmaceuticals Inc Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514751D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Also Published As

Publication number Publication date
WO2017029517A1 (en) 2017-02-23
LT3337477T (lt) 2023-03-10
SMT202300063T1 (it) 2023-03-17
PL3337477T3 (pl) 2023-07-03
JP2018523689A (ja) 2018-08-23
ES2939815T3 (es) 2023-04-27
HRP20230376T1 (hr) 2023-06-23
US20180243313A1 (en) 2018-08-30
US10668077B2 (en) 2020-06-02
HK1251467A1 (en) 2019-02-01
FI3337477T3 (fi) 2023-04-27
CN108348505A (zh) 2018-07-31
EP3337477B1 (en) 2023-02-01
AU2016307885A1 (en) 2018-03-08
EP3337477A1 (en) 2018-06-27
HUE061615T2 (hu) 2023-07-28
US12257254B2 (en) 2025-03-25
RS64095B1 (sr) 2023-04-28
US20210069200A1 (en) 2021-03-11
CA2995898A1 (en) 2017-02-23
AU2016307885B2 (en) 2019-07-25
MX2018001926A (es) 2018-06-19
IL257499A (en) 2018-07-31
CN108348505B (zh) 2021-10-12
PT3337477T (pt) 2023-03-20
CN113786409A (zh) 2021-12-14
DK3337477T3 (en) 2023-02-20
US11291669B2 (en) 2022-04-05
US20230066999A1 (en) 2023-03-02
GB201514760D0 (en) 2015-09-30
CN113786409B (zh) 2024-04-02
KR20180064387A (ko) 2018-06-14

Similar Documents

Publication Publication Date Title
IL257499A (en) Compounds containing as phosphoinositide 3-kinase inhibitors and a second antiproliferative factor
IL257521A (en) Compositions comprising a pi3k inhibitor and an hdac inhibitor
ZA201606074B (en) Compositions comprising a bittering agent
IL263910A (en) Pyrimidine-based antiproliferative agents
IL274006A (en) Compounds that suppress factor Xia or kallikrein and preparations containing them
SMT202000442T1 (it) Composizioni comprendenti una combinazione di ipilimumab e nivolumab
DK3250656T3 (en) Compositions comprising 1,1-difluoroethene, trifluoromethane and a third component
HUE065239T2 (hu) JAK-inhibitort tartalmazó gyógyszerkészítmények
IL247668B (en) Preparations that include dopa decarboxylase inhibitors
SMT202500360T1 (it) Formulazioni/composizioni che comprendono un inibitore di btk
PT3227325T (pt) Composições inibidoras seletivas da sinalização trans de il-6
DK3197936T3 (da) Silanfunktionaliserede forbindelser og sammensætninger deraf
ZA201800821B (en) Compositions against cat allergy
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
IL255219A0 (en) pde10 suppressor compounds, preparations containing them and their uses
GB201614961D0 (en) Compounds and compositions for use
ZA201803212B (en) Gelatinase inhibitors and use thereof
IL253212A (en) Jasmonate derivatives and compositions thereof
GB201504298D0 (en) CT-1 inhibitor
GB201504294D0 (en) CT-1 inhibitor